ARCHIVES

FDA’s Commitment To Cancer No Different Than Other Diseases, Kessler Tells Advocate

This article is from The Cancer Letter archive.

Vol. 18 No. 33 | August 14, 1992

Download PDF Visit The Full Archive

Related Articles

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

September 17, 2010

Drug Development Effort Criticized

April 18, 1975

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

Clinical Trials: For ER+ Breast Cancer, Post-Tamoxifen, NSABP Testing Aromasin In Large Trial

June 1, 2001

NCI Advises Five-Year Limit On Tamoxifen Use, in Letter To Doctors

December 8, 1995

Funding NCI Bypass Budget The “Very Least” Congress Could Do, Congressman Durbin Says

July 13, 1990